Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study
Int. Journal of Clinical Pharmacology and Therapeutics · 01.11.2026 · 64 (11) · 570-581
DOI: 10.5414/cp204974 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.11.2026. Verfasst von Aiko Fukui und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cachexia, Hydrazines, Neoplasms.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Fukui, A., Ota, R., & Hirata, A. (2026). Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study. Int. Journal of Clinical Pharmacology and Therapeutics, 64(11), 570-581. https://doi.org/10.5414/cp204974
Vancouver
Fukui A, Ota R, Hirata A. Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(11):570-581. doi:10.5414/cp204974
BibTeX
@article{Fukui2026,
author = {Fukui, Aiko and Ota, Ryosuke and Hirata, Atsushi},
title = {Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2026},
volume = {64},
number = {11},
pages = {570--581},
doi = {10.5414/cp204974}
}
EUVIMED